Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Expected to Post FY2026 Earnings of $0.06 Per Share

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) – Research analysts at HC Wainwright issued their FY2026 earnings per share estimates for shares of Lineage Cell Therapeutics in a research note issued on Monday, May 6th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings of $0.06 per share for the year. HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.13) per share. HC Wainwright also issued estimates for Lineage Cell Therapeutics’ FY2027 earnings at $0.04 EPS and FY2028 earnings at $0.18 EPS.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $6.00 target price on shares of Lineage Cell Therapeutics in a research note on Monday, February 5th.

Lineage Cell Therapeutics Stock Up 1.7 %

LCTX opened at $1.18 on Thursday. The stock has a market capitalization of $222.78 million, a PE ratio of -9.08 and a beta of 1.39. Lineage Cell Therapeutics has a 1-year low of $0.84 and a 1-year high of $1.61.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last announced its earnings results on Thursday, March 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.04. Lineage Cell Therapeutics had a negative return on equity of 31.95% and a negative net margin of 240.20%. The company had revenue of $2.09 million for the quarter, compared to analyst estimates of $4.74 million.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Fifth Third Wealth Advisors LLC acquired a new position in shares of Lineage Cell Therapeutics in the 1st quarter worth approximately $30,000. SG Americas Securities LLC increased its holdings in shares of Lineage Cell Therapeutics by 61.6% in the fourth quarter. SG Americas Securities LLC now owns 30,889 shares of the company’s stock valued at $34,000 after buying an additional 11,779 shares in the last quarter. Rathbones Group PLC bought a new position in shares of Lineage Cell Therapeutics in the third quarter valued at $41,000. Finally, DCF Advisers LLC lifted its position in shares of Lineage Cell Therapeutics by 14.5% during the 4th quarter. DCF Advisers LLC now owns 94,751 shares of the company’s stock valued at $103,000 after acquiring an additional 12,000 shares during the last quarter. 62.47% of the stock is owned by institutional investors.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.